886362-00-1 Usage
General Description
3-Bromoimidazo[1,2-a]pyridine-6-carboxylic acid is a chemical compound with the molecular formula C8H5BrN2O2. It is a heterocyclic compound containing a pyridine ring fused to an imidazole ring, with a carboxylic acid group attached to the 6-carbon position. 3-BROMOIMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the development of new drugs for various therapeutic purposes, including anti-cancer and anti-inflammatory medication. 3-Bromoimidazo[1,2-a]pyridine-6-carboxylic acid is also utilized in the research and development of new chemical compounds and materials. Its unique structure and properties make it a valuable building block for the creation of diverse organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 886362-00-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 2 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 886362-00:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*2)+(2*0)+(1*0)=201
201 % 10 = 1
So 886362-00-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H5BrN2O2/c9-6-3-10-7-2-1-5(8(12)13)4-11(6)7/h1-4H,(H,12,13)
886362-00-1Relevant articles and documents
Lead optimization of imidazopyrazines: A new class of antimalarial with activity on Plasmodium liver stages
Zou, Bin,Nagle, Advait,Chatterjee, Arnab K.,Leong, Seh Yong,Tan, Liying Jocelyn,Sim, Wei Lin Sandra,Mishra, Pranab,Guntapalli, Prasuna,Tully, David C.,Lakshminarayana, Suresh B.,Lim, Chek Shik,Tan, Yong Cheng,Abas, Siti Nurdiana,Bodenreider, Christophe,Kuhen, Kelli L.,Gagaring, Kerstin,Borboa, Rachel,Chang, Jonathan,Li, Chun,Hollenbeck, Thomas,Tuntland, Tove,Zeeman, Anne-Marie,Kocken, Clemens H. M.,McNamara, Case,Kato, Nobutaka,Winzeler, Elizabeth A.,Yeung, Bryan K. S.,Diagana, Thierry T.,Smith, Paul W.,Roland, Jason
supporting information, p. 947 - 950 (2014/10/15)
Imidazopyridine 1 was identified from a phenotypic screen against P. falciparum (Pf) blood stages and subsequently optimized for activity on liver-stage schizonts of the rodent parasite P. yoelii (Py) as well as hypnozoites of the simian parasite P. cynomolgi (Pc). We applied these various assays to the cell-based lead optimization of the imidazopyrazines, exemplified by 3 (KAI407), and show that optimized compounds within the series with improved pharmacokinetic properties achieve causal prophylactic activity in vivo and may have the potential to target the dormant stages of P. vivax malaria.
